Discussion
This is the first study of paediatricians’ experiences of providing care to patients with rare diseases using a representative, systematically recruited sample (n=242). Almost all (98%) of paediatricians in our survey had encountered patients with rare diseases or unusual undiagnosed syndromes in their clinical career. Approximately one-third had seen ≥100 diagnosed cases representing a wide variety of conditions. Almost three-quarters saw a new case in the last 6 months. Our results align with the reported high economic burden of genetic disorders in a population-based study in Western Australia.8
Paediatricians experienced problems when caring for children with rare diseases, most commonly delay or inability to make a definitive diagnosis. This was attributed to difficulties accessing diagnostic tests including genetic tests. In Australia, the number of tests covered by the publicly funded Medicare Benefits Scheme has remained static but new tests have become available, many of which are not covered, leading to potential inequitable access to genetic testing according to the individual’s financial situation.19 Similar concerns about access to genetic tests have been reported by patients’ families.5 6 Paediatricians also reported delays in interpretation of genetic tests, suggesting a need for increased clinical genetics capacity in Australia. The burden on clinical geneticists will undoubtedly increase with availability of cheaper sequencing, however delays in clinical interpretation of variants and diagnostic delays should ultimately diminish.20
The lack of clinical guidelines, lack of treatment options and inability to access drugs that there are available overseas but not licensed in Australia also frustrates paediatricians. Paediatricians reported difficulties in accessing allied health services and uncertainties about referral pathways. Parents also report problems in accessing treatments, allied health services and care coordination.4–6
A report by the pharmaceutical company Shire involving 50 physicians from the USA and 50 from UK showed that they needed to see rare disease patients more frequently than other patients for diagnosis and monitoring and found coordinating their care difficult.14 This concurs with our studies of paediatricians and parents.4–6 A large proportion of physicians in the Shire report (USA 86%; UK 90%) reported difficulties accessing treatments, compared with only 40% in our study. This stark difference is not easily explained given that more rare drugs are licensed in the USA and UK than in Australia. The Shire report had a small sample and did not describe the selection, recruitment and representativeness of the respondents, making comparisons difficult.14
Our study is the first to highlight paediatricians’ awareness and use of educational resources, specifically when caring for patients with rare diseases. Only 57% said their medical degree prepared them to recognise patients with rare diseases and one-third felt ‘unprepared’ to care for children with rare diseases. The French National Plan for Rare Diseases stipulates that the undergraduate medical curriculum must include specific education in rare diseases, including how to access reliable information.21 There is no such requirement in Australia, and almost 40% of respondents in our study lacked confidence about finding reliable information about rare diseases.
The majority were aware of, and used online educational resources including Medline, the Cochrane Library, and the NICE guidelines to support their clinical practice. Fewer were aware of, or had used, rare disease specific resources such as OMIM, POSSUM and the Orphanet portal. Only 35% were aware of the NORD portal, which houses ‘Physician Guides’ for over 1200 rare diseases22 and only 22% were aware of the New South Wales Health Centre for Genetics Education.23
Almost 90% were aware of APSU resources on rare diseases for example, case definitions, surveillance protocols and reports and just over half had used these resources. This high level of awareness of APSU resources was likely biased as the sample was drawn from the APSU. The relatively low use of APSU resources may depend on the paediatrician seeing a child with one of the 60 rare conditions for which APSU provides resources. APSU plans to extend the reach and usefulness of these resources for clinicians.
The APSU database was estimated to represent ~90% of Australian paediatricians in active clinical practice.17 18 The relatively small response fraction and the likelihood of response from paediatricians who are interested in, or have exposure to patients with rare diseases, might have introduced some bias. Nevertheless the sample was large and representative across states/territories, specialties and subspecialties, and the response fraction is similar to other surveys of busy health professionals.
Paediatricians called for rare disease resources to be made available via a single portal to simplify searching for information. The majority (82%) wanted a directory of specialist referral services for rare diseases, despite only 21% being uncertain about referral pathways. Importantly, over 90% of paediatricians called for easily available printable fact sheets for patients and families, and a directory of family support groups to which families could be referred. Although Genetic Alliance Australia (formerly AGSA) provides counselling services and links to peer support groups for many genetic diseases, few paediatricians knew about this valuable service.
Paediatricians said they would be more likely to use online resources than printed materials or face-to-face opportunities for education. Availability of online resources and awareness of these is essential to support their use in clinical practice, as needed. Female paediatricians and paediatricians aged <50 years would be more likely to use smartphone apps in clinical practice and these groups should be targeted if rare diseases apps were to be developed.
The APSU website houses information about many rare diseases, and provides links to well-respected resources such as OMIM and the Orphanet portal. Because APSU is well known to many Australian paediatricians and other child health clinicians, there is opportunity to build on existing infrastructure to develop a comprehensive information and educational portal with links to high-quality resources nationally and internationally. Furthermore, there is an opportunity to pool resources and to reach paediatricians in at least 11 countries through the International Network of Paediatric Surveillance Units.24
Our results support the need to raise awareness of rare disease resources while consolidating and disseminating via a single portal. To improve awareness, access to and actual use of resources in clinical practice, multiple strategies are needed to engage with paediatricians. Embedding specific teaching about rare diseases in undergraduate and postgraduate medical curricula would better equip future paediatricians to care for children with rare diseases. Paediatricians also need access to affordable genetic tests for their patients and to clinical geneticists’ expertise to support meaningful clinical decisions.